Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult Cohort
- Written by PR Newswire
-- Bivalent SCB-1019 significantly boosted RSV-A and RSV-B neutralization titers to approximately 6,600 IU/mL (6.4-fold increase) and approximately 46,000 IU/mL (12-fold increase), respectively --
-- Preliminary Phase I data in target older adult population is on track for H2-2024 --
SHANGHAI, April 8, 2024 /PRNewswire/ -- Clover Biopharmaceuticals,...
